Analytical method transfer is the documented process that qualifies a laboratory (the receiving unit) to run an analytical procedure developed and validated elsewhere (the transferring unit). It happens more often than you might think: a product moves from development to site QC, a test is shifted to an overseas manufacturing site, an activity is outsourced to a contract laboratory. In all these cases the method "already works" — but nobody has yet demonstrated that it works in that laboratory, with those instruments and those analysts. This is exactly what USP <1224> and EU GMP Chapter 6 focus on, and where inspectors find the most frequent gaps: transfers done "by email", with no protocol, no acceptance criteria and no report.
Analytical method transfer: what USP <1224> says
USP General Chapter <1224> Transfer of Analytical Procedures defines the transfer (TAP) as the documented process that qualifies the receiving laboratory to use an analytical procedure that originated in another laboratory, ensuring it has the procedural knowledge and the ability to perform it as intended. There are two roles, each with precise responsibilities:
- Transferring unit (typically the development laboratory): provides the procedure, reference standards, validation reports and the necessary documentation, along with training and assistance to the receiving site.
- Receiving unit (site QC, another facility within the group or an external laboratory): ensures trained personnel, qualified and calibrated instruments, and laboratory systems that comply with applicable regulations.
The two units compare data, discuss any deviations from the protocol and agree on the corrections to capture in the final report or in the procedure itself. A transfer is therefore not a one-way handover but a joint exercise with a measurable outcome.
The four transfer approaches
USP <1224> recognises four approaches, to be chosen based on risk and context. The table summarises them:
| Approach | How it works | When to use it |
|---|---|---|
| Comparative testing | Both laboratories analyse samples from the same lot under a pre-approved protocol with predetermined acceptance criteria | The most common approach, suitable for most quantitative methods |
| Covalidation | The receiving laboratory takes part in the method validation together with the transferring unit, generating interlaboratory reproducibility data | When validation and transfer can be planned together |
| Revalidation | The receiving unit repeats the validation, in full or in part, limited to the USP <1225> characteristics the transfer may affect | When direct comparison is not practical or the method is modified |
| Transfer waiver | The conventional transfer is omitted, with a documented justification | Only in the specific cases foreseen by the chapter (see below) |
The waiver deserves attention because it is the most abused option. USP <1224> allows it, for example, when the new product's composition or active concentration is comparable to one already tested with the same procedures, when the method is compendial and unchanged (verification under USP <1226> applies instead), when the procedure is identical or very similar to one already in use, or when the personnel who developed and validated the method have moved to the receiving laboratory. In every case the justification must be written down and approved: an undocumented waiver is, in an inspection, equivalent to a transfer never performed.
Transfers, validations and pharmacopoeia updates change faster than SOPs can keep up. With The Pragmatic GMP, GuideGxP's free weekly newsletter, you get USP, Ph. Eur. and GMP updates already translated into operational actions for your laboratory every week: subscribe and arrive prepared for your next transfer.
What EU GMP Chapter 6 requires
On the European side, Chapter 6 (Quality Control) of EudraLex Volume 4 dedicates paragraphs 6.37 to 6.41 to the technical transfer of testing methods, introduced with the revision in operation since 1 October 2014. The key requirements:
- Pre-transfer verification and gap analysis (6.37). Before the transfer, the transferring site verifies that the method complies with the marketing authorisation dossier and reviews the original validation against current ICH/VICH requirements: the gap analysis must be documented and any supplementary validation completed before starting.
- Detailed protocol (6.38–6.39). The transfer follows a protocol identifying the tests and methods being transferred, additional training needs, standards and samples to be tested, special transport and storage conditions, and acceptance criteria based on the current validation of the method.
- Deviations and report (6.40). Deviations from the protocol must be investigated before closing the transfer; the report documents the comparative outcome and identifies any further revalidation needed.
- Specific methods (6.41). For particular techniques, such as near-infrared spectroscopy, the requirements of dedicated European guidelines apply.
The picture is completed by the WHO guidelines on technology transfer (TRS 1044, Annex 4, 2022), which frame analytical method transfer within the overall site-to-site technology transfer, and by ICH Q14, whose lifecycle approach to the analytical procedure turns development knowledge into direct support for future transfers.
Protocol and acceptance criteria: the critical points
In practice, the quality of a transfer comes down to three elements of the protocol:
- The experimental design. How many analysts, how many days, how many replicates per site: the design must allow the receiving laboratory's variability to be estimated (for example as %RSD or intermediate precision) and compared with the transferring unit's. For dissolution, USP <1224> also mentions profile comparison using the f2 similarity factor.
- The samples. A single lot is sufficient, because the transfer evaluates the method's performance at the new site, not the manufacturing process. Aged or spiked samples, chosen wisely, help reveal sample-preparation issues that an "easy" lot would hide.
- Failure management. The protocol must establish in advance how a failed criterion will be handled: any change after a failure must be approved before new data is generated, otherwise the transfer turns into indefensible "testing into compliance".
The most frequent audit findings are always the same: transfers executed without an approved protocol, acceptance criteria copied from the validation without considering interlaboratory variability, undocumented training of receiving-site personnel, deviations closed without investigation, and reports lacking a statistical comparison between the two sites. Plus the classic: a compendial method declared "not subject to transfer" but never verified under USP <1226> or EU GMP 6.15.
GuideGxP recommendation
Treat the transfer as a project, not a formality: appoint an owner for each unit, start from the gap analysis required by Chapter 6 (that is where validations outdated against ICH Q2(R2) surface) and choose the transfer approach based on the method's risk, not on habit. Have the receiving laboratory run an informal trial before signing the protocol: issues with columns, reagents or interpretation of the procedure should emerge before the formal phase, not during it. And keep in the report what went wrong and how it was resolved: in an inspection, a transfer with investigated deviations is more defensible than a "perfect" one with no evidence.
If you work with USP, Ph. Eur. and compendial methods every day, our guide Pharmacopoeias in GMP – Operational Guide to USP, Ph. Eur., JP and BP covers the general chapters relevant to the QC laboratory, the verification rules and the operational templates that make compendial choices defensible in audit.
